World-first pig kidney trials mark turning point for xenotransplantation


AI Summary Hide AI Generated Summary

Xenotransplantation Breakthrough

The article reports on the US Food and Drug Administration's (FDA) approval of the first clinical trial involving the transplantation of genetically modified pig kidneys into humans. This represents a major turning point in xenotransplantation, a field previously hampered by immunological rejection, viral transmission risks, and ethical considerations.

Significance

Prior to this, xenotransplantation was limited to individual cases under compassionate use protocols. This first-in-human clinical trial has the potential to establish xenotransplantation as a standard medical procedure, offering a life-saving solution for thousands annually facing organ failure.

Challenges Overcome

The success is particularly noteworthy given the historical challenges of xenotransplantation. The article highlights the significant hurdles related to immune system rejection and the risk of cross-species viral infections which have been overcome to enable this clinical trial.

Sign in to unlock more AI features Sign in with Google

For decades, the promise of xenotransplantation β€” the transplantation of organs from animals into humans β€” has remained just beyond reach. The field has long been dogged by immunological rejection, concerns over viral transmission and ethical dilemmas1. But in February 2025, a pivotal moment was reached when the US Food and Drug Administration approved the first clinical trial testing whether kidneys from genetically modified pigs could be safely transplanted into humans. Until then, xenotransplantation had been limited to individual cases approved under compassionate use or expanded access protocols. This pathway allows patients with serious, life-threatening illnesses to access experimental treatments when no other comparable options are available. A first-in-human clinical trial could lay the foundation for xenotransplantation to become a routine medical treatment, potentially saving thousands of lives each year.

Access options

Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout

Additional access options:

doi: https://doi.org/10.1038/d41591-025-00020-0

The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.

Was this article displayed correctly? Not happy with what you see?

Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device